ADT-1004: A First-in-Class, Oral Pan-RAS Inhibitor with Robust Antitumor Activity in Preclinical Models of Pancreatic Ductal Adenocarcinoma

Investigators developed a novel pan-RAS inhibitor, ADT-1004 and evaluated antitumor activity in murine and human PDAC models. ADT-1004 had strong antitumor activity in aggressive and clinically relevant PDAC models with unique selectivity to block RAS-mediated signaling in RAS mutant cells.